Infection News

Alcohol use at initiation of direct-acting antiviral treatment was not associated with reduced odds for achieving sustained virologic response among veterans with chronic hepatitis C virus infection, according to data in JAMA Network Open.

Nearly half a million Americans are diagnosed with Clostridioides difficile infection each year. Although often treated with antibiotics, C. difficile recurrence is possible. However, recently developed therapies may change this paradigm.

The FDA approved the supplemental new drug application for Talicia for Helicobacter pylori eradication, shortening the current dosing regimen to improve patient adherence, according to manufacturer RedHill Biopharma.

PHILADELPHIA — In this video, Claudine Kabera, MPH, an epidemiologist at the FDA’s Center for Veterinary Medicine, discusses the U.S. government’s efforts to monitor the food supply for antimicrobial resistance.

ISA Pharmaceuticals announced that the first patient has been treated in its first-in-human phase 1 trial of its novel immunotherapeutic agent intended as a “functional cure” for patients with chronic hepatitis B virus infection.

Global burden of hepatitis B virus is estimated to be 257.5 million individuals, according to recent data in Lancet Gastroenterology & Hepatology, which, although lower than current WHO estimates, falls short of 2030 elimination targets.

Researchers estimated that the introduction of generic medications for chronic hepatitis B virus infection could save Medicare Part D nearly $300 million annually from the cost of medication alone, according to data in Gastroenterology.

Maternal hepatitis B virus serostatus was not associated with pregnancy outcomes in infertile women in China who underwent freeze-thaw embryo transfer, according to data in JAMA Network Open.

An FDA-approved oral fecal microbiota therapeutic reduces the risk for recurrent Clostridioides difficile infection in high-risk patients compared with placebo, regardless of demographics or baseline risk factors, researchers reported.

A personal injury law firm has filed a lawsuit against Novo Nordisk and Eli Lilly, alleging the manufacturers “downplayed the severity of the gastrointestinal events caused by Ozempic and Mounjaro,” such as gastroparesis and gastroenteritis.